Chronic Obstructive Pulmonary Disease, Lung Function and Quality of Life in Adult Chinese

2012 ◽  
Keyword(s):  
Quality Of Life ◽  
Chronic Obstructive Pulmonary Disease ◽  
Lung Function ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

Roflumilast Improves Lung Function and Quality of Life in Chronic Obstructive Pulmonary Disease

CHEST Journal ◽  
2004 ◽  
Vol 126 (4) ◽  
pp. 709S ◽  
Author(s):  
Klaus F. Rabe ◽  
D. O’Donnell ◽  
E.D. Bateman ◽  
K. Andrae ◽  
S. Witte ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Obstructive Pulmonary Disease ◽  
Lung Function ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

scholarly journals AMELIORATION OF QUALITY OF LIFE AND LUNG FUNCTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY PRANIC HEALING AS ADJUVANT THERAPY

2017 ◽  
Vol 10 (08) ◽  
Author(s):  
Jois Nagaraja Srikanth ◽  
Mysore Srinivasachar Ananthakrishna ◽  
Gurumurthy Parthasarathi ◽  
Sindaghatta Krishnarao Chaya ◽  
Rajendra Rajgopal ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Obstructive Pulmonary Disease ◽  
Lung Function ◽  
Adjuvant Therapy ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

scholarly journals Role of tiotropium in chronic obstructive pulmonary disease exacerbation

1970 ◽  
Vol 32 (2) ◽  
pp. 5-10
Author(s):  
P Pant ◽  
B Yadav ◽  
GM Khan ◽  
R Koju ◽  
R Gurung ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Obstructive Pulmonary Disease ◽  
Cost Effectiveness ◽  
Side Effects ◽  
Lung Function ◽  
Pulmonary Disease ◽  
Ipratropium Bromide ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

Introduction: Chronic obstructive pulmonary disease (COPD) remains a major public health problem. Many patients suffering from chronic obstructive lungs diseases are of poor economic status, mostly illiterate, therefore has a direct bearing on patient compliance. Tiotropium is a new anticholinergic therapy for chronic obstructive pulmonary disease that differs from ipratropium by its functional relative selectively for musarinic receptor subtypes and which allows single dosing a day. This study presents a cost-effectiveness, efficacy, and side-effects of Ipratropium bromide and Tiotropium in COPD. Methods: Prospective study was conducted In Kathmandu University Teaching Hospital, between the year 2008 and 2009 in terms of cost-effectiveness, efficacy, and side-effects of Tiotropium and Ipratropium amongst COPD patients. Results: Tiotropium and Ipratropium were prescribed in total of 57 patients (30 in ipratropium bromide and 27 in tiotropium bromide) for the management of COPD among outpatients. There were no significant differences in age, height, weight and baseline lung function parameters (FEV1 and PEF) between the two drugs i.e. ipratropium bromide and tiotropium bromide. Significant improvement in lung function parameters were found in each respective group of drugs after bronchodilator therapy. Tiotropium results in significant reduction of Chronic Obstructive Pulmonary disease exacerbations and significant improvement in quality of life, lung function, and dyspnoea compared to ipratropium. The additional cost to achieve these favorable outcomes was cheaper than Ipratropium bromide. (Nepalese Rs. 7.03 per day for tiotropium as compared to Rs. 9.06 for Ipratropium) Conclusions: Tiotropium results in significant reduction of chronic obstructive pulmonary disease exacerbations and significant improvement in quality of life, lung function and dyspnoea compared to Ipratropium. Keywords: Chronic obstructive pulmonary disease; ipratropium; tiotropium DOI: http://dx.doi.org/10.3126/joim.v32i2.4937 Journal of Institute of Medicine, August, 2010; 32: 5-10

Sign in / Sign up

Export Citation Format

Share Document